Volume
Open
Day's Low
Day's High
52 Wk Low
52 Wk High
Bid
Ask
EPS
PE Ratio
Shares
Market Cap
Dividend
Ex-Div Date
Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
...
Health Technology » Biotechnology
| symbol | company | %chng | last | %short | avg$volume | |
|---|---|---|---|---|---|---|
| VTL | Vital Therapies, Inc. | 1.50% | 13.51 | 3.3% | $792.68m | |
| AMGN | Amgen Inc. | 2.36% | 204.02 | 1.3% | $749.47m | |
| GILD | Gilead Sciences, Inc. | 0.43% | 63.14 | 0.9% | $384.23m | |
| CELG | Celgene Corporation | 1.53% | 94.74 | 1.3% | $360.74m | |
| ILMN | Illumina, Inc. | 0.49% | 286.17 | 3.5% | $321.19m | |
| BIIB | Biogen Inc. | 1.78% | 231.68 | 1.3% | $305.34m | |
| VRTX | Vertex Pharmaceuticals Incorporated | 2.11% | 184.94 | 1.9% | $260.38m | |
| EXAS | Exact Sciences Corporation | 1.35% | 119.82 | 24.1% | $245.81m | |
| ALXN | Alexion Pharmaceuticals, Inc. | 1.66% | 110.85 | 2.0% | $238.74m | |
| REGN | Regeneron Pharmaceuticals, Inc. | 1.28% | 296.85 | 2.6% | $212.35m | |
| A | Agilent Technologies, Inc. | 2.18% | 71.11 | 1.6% | $206.33m | |
| SRPT | Sarepta Therapeutics, Inc. | 2.44% | 124.95 | 14.7% | $156.17m | |
| INCY | Incyte Corporation | 3.11% | 83.12 | 2.5% | $97.22m | |
| BMRN | BioMarin Pharmaceutical Inc. | 6.65% | 76.50 | 4.3% | $91.98m | |
| SGEN | Seattle Genetics, Inc. | 3.25% | 79.20 | 6.5% | $90.21m |
Company Profile
La Jolla Pharmaceutical Co. operates as a biopharmaceutical company, which engages in the discovery, development and commercialization of therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases. Its products includes LJPC-501, LJPC-401 and LJPC-0118. LJPC-501 is the proprietary formulation for angiotensin II. The LJPC-401 is the formulation of hepcidin, which is an endogenous peptide hormone and LJPC-0118 is La Jolla's investigational product for the treatment of severe malaria. The company was founded in 1989 and is headquartered in San Diego, CA.